Autoplaque vs AVIEW LCS

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Autoplaque

by APQ Health (formerly Cedars-Sinai Medical Center: AIM)

AVIEW LCS

by Coreline Soft Co.

AI Verdict

Autoplaque is a specialized tool for detailed quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, focusing on heart attack risk prediction. AVIEW LCS offers a broader cardiopulmonary assessment from low-dose CT scans, primarily for lung cancer screening, but also includes coronary artery calcification (CAC) scoring. While both contribute to cardiovascular risk assessment, Autoplaque offers more granular plaque characterization, whereas AVIEW LCS provides a multi-organ assessment with CAC scoring as one component.

Choose Autoplaque if…

Choose Autoplaque if your primary need is a highly detailed, AI-powered quantitative analysis of coronary atherosclerotic plaque and luminal stenoses from CT angiography images. This tool is ideal for clinicians focused specifically on precise plaque characterization and stenosis measurement to inform heart attack risk prediction and guide targeted cardiovascular treatment strategies.

View Autoplaque →

Choose AVIEW LCS if…

Choose AVIEW LCS if you require a comprehensive AI solution for integrated lung cancer screening, COPD assessment, and coronary artery calcification scoring from a single low-dose CT scan. This platform is best suited for radiology departments and screening programs aiming to streamline workflows and enhance diagnostic accuracy across multiple cardiopulmonary conditions with automated reporting and nodule tracking.

View AVIEW LCS →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Autoplaque	AVIEW LCS
Pricing	Unknown	Contact for pricing
Deployment	Workstation-based post-processing application, runs on Windows or Mac OS.	Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AVIEW LCS

AVIEW LCS offers superior deployment flexibility, supporting cloud, hybrid, local, and virtualized solutions, along with explicit integration capabilities with PACS/RIS and third-party platforms. This broad compatibility and integration streamline clinical workflows more effectively than Autoplaque's workstation-based approach. Additionally, AVIEW LCS provides comprehensive automated reporting and 3D visualization, enhancing clarity for clinicians and patient communication.

Clinical Value

AVIEW LCS

AVIEW LCS provides a more comprehensive clinical assessment by integrating the analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan. This 'Big 3' screening capability offers broader diagnostic insights and workflow efficiency compared to Autoplaque's focused analysis of coronary plaques and stenoses. AVIEW LCS has also demonstrated high sensitivity in nodule detection and significant potential for radiologist workload reduction in large-scale clinical validation studies.

Pricing & Value

Tie

Both Autoplaque and AVIEW LCS have undisclosed pricing, making it impossible to conduct a direct comparison of their cost-effectiveness. While AVIEW LCS's multi-faceted diagnostic capabilities might suggest greater value, without transparent pricing for either product, a definitive winner cannot be determined in this dimension.

Enterprise Readiness

AVIEW LCS

AVIEW LCS demonstrates superior enterprise readiness through its explicit HIPAA compliance and availability of Business Associate Agreements (BAA), which are critical for healthcare organizations. Its diverse deployment options (cloud, hybrid, local, virtualized) and stated integration with PACS/RIS and third-party platforms ensure greater adaptability and seamless adoption within complex IT infrastructures. Autoplaque's workstation-based deployment and lack of explicit compliance statements in the provided data make it less suitable for broad enterprise implementation.

Innovation

AVIEW LCS

AVIEW LCS showcases greater innovation by offering an integrated, fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan. This multi-disease screening approach, leveraging advanced AI for CT kernel conversion, represents a significant advancement in diagnostic efficiency and comprehensive patient assessment. While Autoplaque's AI-powered plaque analysis is innovative, AVIEW LCS's broader, integrated screening capability from a single input is a more transformative innovation in the field.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer sufficient public information regarding specific support channels, service level agreements, or comprehensive user documentation for either Autoplaque or AVIEW LCS. Therefore, a meaningful comparison in this dimension is not possible.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Autoplaque	AVIEW LCS
Tool Name	Autoplaque	AVIEW LCS
Company	Cedars-Sinai Medical Center: AIM	Coreline Soft Co.
Primary Focus	AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images.	AI-powered solution for detection and analysis of lung nodules, with integrated analysis of lung cancer, COPD, and coronary artery calcification from low-dose CT.
Key Analytical Capabilities	AI-powered quantitative analysis of atherosclerotic plaque, detection and characterization of coronary artery plaque, measurement of luminal stenoses, automated vessel/plaque/lumen segmentation.	Automated lung nodule detection and analysis, Lung-RADS classification, nodule volume quantification, emphysema quantification, Coronary Artery Calcification (CAC) scoring.
Specialties	Cardiology, Radiology	Cardiology, Oncology, Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring Autoplaque and AVIEW LCS.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of each tool?

Autoplaque is an AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. AVIEW LCS is an AI-powered solution for the detection and analysis of lung nodules, and the AVIEW LCS Plus platform provides integrated, fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan.

How do the cardiac assessment capabilities of Autoplaque and AVIEW LCS differ?

Autoplaque focuses on AI-powered quantitative analysis of atherosclerotic plaque and measurement of luminal stenoses from CT angiography. AVIEW LCS Plus, on the other hand, provides coronary artery calcification (CAC) scoring (Agatston, volume, mass) from low-dose CT scans.

What types of CT scans are required for each tool?

Autoplaque analyzes coronary plaques and luminal stenoses from CT angiography images. AVIEW LCS processes low-dose CT scans for lung nodule detection, COPD assessment, and coronary artery calcification.

Does either tool offer integrated analysis beyond cardiac assessment?

Autoplaque is specialized for coronary plaque and stenosis analysis. AVIEW LCS Plus offers integrated, fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan.